Meine Merkliste  

2.732 Aktuelle Fachpublikationen von Future Medicine


Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients

25.02.2015 | Silvo Koder; Katja Repnik; Ivan Ferkolj; Cvetka Pernat; Pavel Skok; Rinse K Weersma; Uroš Potočnik, Pharmacogenomics, 2015

Aim: To see if SNPs could help predict response to biological therapy using adalimumab (ADA) in Crohn's disease (CD). Materials & methods: IBDQ index and CRP levels were used to monitor therapy response. We genotyped 31 CD-associated genes in 102 Slovenian CD patients. Results: The strongest ...


Pharmacogenomics toward personalized tamoxifen therapy for breast cancer

25.02.2015 | Hitoshi Zembutsu, Pharmacogenomics, 2015

Tamoxifen has been used not only for the treatment or prevention of recurrence in patients with estrogen receptor positive breast cancers but also for recurrent breast cancer. Because CYP2D6 is known to be an important enzyme responsible for the generation of the potent tamoxifen metabolite, ...


Nurses’ communication of pharmacogenetic test results as part of discharge care

25.02.2015 | Susanne B Haga; Rachel Mills, Pharmacogenomics, 2015

As pharmacogenetic (PGx) testing is becoming integrated into routine clinical procedures for admitted hospital patients, consideration is needed as to when test results will be communicated to patients and by whom. Given the implications of PGx test results for current and future care, we propose ...


Expansion of pharmacogenomics into the community pharmacy: billing considerations

25.02.2015 | Shanna K O’Connor; Natasha Michaels; Stefanie Ferreri, Pharmacogenomics, 2015

Pharmacogenomics March 2015, Vol. 16, No. 3, Pages 175-180.


Genetic variations in NADPH-CYP450 oxidoreductase in a Czech Slavic cohort

25.02.2015 | Mária Tomková; Satya Prakash Panda; Ondřej Šeda; Alice Baxová; Martina Hůlková; Bettie Sue Siler Masters; Pavel Martásek, Pharmacogenomics, 2015

Aim: Estimating polymorphic allele frequencies of the NADPH–CYP450 oxidoreductase (POR) gene in a Czech Slavic population. Methods: The POR gene was analyzed in 322 individuals from a control cohort by sequencing and high resolution meltinganalysis. Results: We identified seven unreported SNP ...


Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis

25.02.2015 | Nora Kupstyte; Remigijus Zaliunas; Vacis Tatarunas; Vilius Skipskis; Diana Zaliaduonyte-Peksiene; Ingrida Grabauskyt ..., Pharmacogenomics, 2015

Aim: To determine the main clinical and genetic factors having impact on early coronary stent thrombosis. Materials & methods: Genotyping of CYP2C19*2, *17 and CYP4F2*3 in patients with (n = 31) and without stent thrombosis (n = 456) was performed. Clinical and genetic data were analyzed by ...


Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas

25.02.2015 | Elizabeth H Dorfman; Susan Brown Trinidad; Chelsea T Morales; Kevin Howlett; Wylie Burke; Erica L Woodahl, Pharmacogenomics, 2015

Aim: The limited formal study of the clinical feasibility of implementing pharmacogenomic tests has thus far focused on providers at large medical centers in urban areas. Our research focuses on small metropolitan, rural and tribal practice settings. Materials & methods: We interviewed 17 ...


Factors influencing pharmacokinetics of warfarin in African–Americans: implications for pharmacogenetic dosing algorithms

25.02.2015 | Rui Nagai; Minami Ohara; Larisa H Cavallari; Katarzyna Drozda; Shitalben R Patel; Edith A Nutescu; Minoli A Perera; ..., Pharmacogenomics, 2015

Aim: This study attempted to identify predictors of S-warfarin clearance (CL[S]) and to make a pharmacokinetic evaluation of genotype-based dosing algorithms in African–Americans. Methods: Using plasma S-warfarin concentration (Cp[S]) at a steady state and eight SNPs previously shown to influence ...


In vitro human cell line models to predict clinical response to anticancer drugs

25.02.2015 | Nifang Niu; Liewei Wang, Pharmacogenomics, 2015

In vitro human cell line models have been widely used for cancer pharmacogenomic studies to predict clinical response, to help generate pharmacogenomic hypothesis for further testing, and to help identify novel mechanisms associated with variation in drug response. Among cell line model systems, ...


Donor IL-18 rs5744247 polymorphism as a new biomarker of tacrolimus elimination in Chinese liver transplant patients during the early post-transplantation period: results from two cohort studies

25.02.2015 | Junwei Fan; Xiaoqing Zhang; Lei Ren; Dawei Chen; Shaohan Wu; Feng Guo; Shengying Qin; Zhaowen Wang; Zhong Lin; Tongh ..., Pharmacogenomics, 2015

Aim: This study evaluated the relationships between IL-18 polymorphisms and tacrolimus elimination in Chinese liver transplant patients. Patients & methods: Eighty-four liver transplant patients from Shanghai (training set) and 50 patients from Shandong (validating set) were inculded. IL-18 ...


Seite 3 von 274
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.